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Transfemoral versus transapical approach
for transcatheter aortic valve implantation:
hospital outcome and risk factor analysis.
Enrico Ferrari1,2*, Eric Eeckhout3, Sanjiv Keller2, Olivier Muller3, Piergiorgio Tozzi2, Denis Berdajs4
and Ludwig Karl von Segesser2
Abstract
Background: Transcatheter aortic valve implantation is indicated in high-risk patients with aortic stenosis. We
compared the clinical outcome of 180 consecutive patients who underwent transapical (TA) and transfemoral (TF)
procedures in a single centre.
Methods: Ninety consecutive TA (TA-group) and 90 consecutive TF (TF-group) were performed from 2009 to 2014.
Clinical variables were prospectively collected and retrospectively analysed for hospital outcomes and to identify
risk factors for hospital mortality, vascular complications and stroke.
Results: Mean age was 80 ± 8.5 and 83 ± 8.4 years, in the TA and TF-group, respectively. TA-group presented
higher prevalence of comorbidities: more vascular disease (79% vs 22%, p < 0.001), chronic pulmonary disease (32%
vs 10%, p < 0.001), previous vascular surgery (14% vs 4%, p = 0.039), coronary disease (60% vs 40%, p = 0.007), and
previous cardiac surgery (28% vs 17%, p = 0.073). Logistic Euroscore was 36 ± 15% in the TA-group and 25 ± 14%
in the TF-group (p < 0.001), but hospital mortality was similar (TA:9%, TF:10%, p = 0.799). Access-related vascular
complications occurred more often in transfemoral patients (TA:3%, TF:11%, p = 0.081) while major bleeding (TA:3%,
TF:4%, p = 1) and stroke (TA:2%, TF:3%, p = 1) were equally distributed. Postoperative renal failure and dialysis were
associated with impaired neurological outcome (p = 0.035 and p = 0.020, respectively). Mild to severe paravalvular
leak was more prevalent in transfemoral patients (TA:5%, TF:25%, p < 0.001).
Conclusions: In our experience, the TA and TF-group presented different risk profiles but mortality rate and
adverse neurological outcome had a similar incidence. The transfemoral approach carried more vascular
complications and paravalvular leaks but last-generation devices will improve this outcome.
Keywords: Transcatheter aortic valve implantation, Aortic valve stenosis, Transfemoral aortic valve implantation,
Transapical aortic valve implantation
Background
Aortic stenosis is the most common acquired heart valve
disease in the adult and the surgical aortic valve replace-
ment (SAVR) remains the treatment of choice with good
outcomes and long-term results [1–4]. However, patients
with comorbidities carry a higher surgical risk and,
therefore, they might benefit from recently developed
minimally invasive techniques and technologies. Since
2007, the transcatheter aortic valve implantation (TAVI)
has become a widely-accepted alternative to open heart
surgery in patients with high-risk profiles and, so far,
more than 200′000 procedures have already been per-
formed worldwide, mostly with the CoreValve™ (Medro-
nic, Minneapolis, MN) and the SAPIEN™ (Edwards
Lifesciences, Irvine, CA) valve families with good hospital
and mid-term results [5–8]. The two arms of the PART-
NER trial have proven the safety and efficacy of TAVI in
inoperable and high-risk patients with superior results
when compared to medical treatment and non-inferior
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results when compared to standard surgery [7, 8]. More-
over, recently published studies have also shown good
valve hemodynamic parameters in early and mid-term
follow-ups and in intermediate-risk patients [9–15].
Alternative access routes have been explored but the
two most popular are still the transapical (TA) and the
transfemoral (TF): however, patient attribution to these
accesses is still questionable in absence of a severe per-
ipheral vascular disease. We compared the outcome of
our first 180 consecutive TA and TF TAVI patients and
we identified risk factors for postoperative hospital mor-
tality, vascular complications and stroke.
Methods
In the database, we identified the first 90 TA-TAVI cases
(TA-group) and the first 90 TF-TAVI cases (TF-group)
performed from 2009 to 2014. In our institution, TA-
TAVI was performed since 2009 while TF-TAVI were
scheduled since 2010. During the same period of time,
only few transaortic TAVI have been performed and they
are not included in the study.
Clinical variables were prospectively collected in the
hospital database and then retrospectively analysed to
compare the two groups and to identify risk factors for
hospital mortality (30 days mortality or within hospital
stay), neurological events (stroke) and vascular compli-
cations (major vascular complications including access-
site related complications, aortic dissections, aortic root
rupture and tamponade due to ventricular rupture)
using the VARC-2 definitions described elsewhere [16].
All patients signed informed consents for the index pro-
cedure, for the use of clinical data in medical research
and for clinical data analysis (Patients included in the
Swiss TAVI Registry approved by the Ethics Committee
of the Vaud State in Switzerland).
Patients selection criteria
Patients suffering from severe symptomatic aortic valve
stenosis with concomitant comorbidities were studied for
inclusion in the TAVI program. Standard inclusion criteria
for TAVI were used to identify good candidates and the
Logistic Euro-SCORE was calculated for all patients to
predict hospital mortality. In order to proceed with trans-
catheter interventions the final decision came from the
hospital Heart-Team, in particular concerning patients
not fulfilling standard criteria (i.e. younger patients with
severe liver disease or patients with porcelain aortas).
Important exclusion criteria for both TA and TF ap-
proach were the presence of concomitant severe valvular
or coronary disease not suitable for percutaneous pro-
cedure, severe left ventricular dysfunction with ejection
fraction below 20% and severe patient frailty evaluated
by the Heart-Team, which consists of a cardiologist, a
surgeon (both coordinators for the TAVI program), an
anaesthesiologist, a radiologist and a geriatrician.
An important observation is that during the study
period, transapical and transfemoral procedures were
not equally distributed (Fig. 1). This was due to the
access-site selection process performed by the Heart-
Team that embraced, during the years, the launch of
new “low-profile” transfemoral devices leading to more
valves implanted transfemorally.
All patients enrolled in the TAVI program underwent
complementary trans-thoracic echocardiogram, coronary
angiogram and three-dimensional cardiovascular computed
tomography scan (3D CT-scan) to analyse alternative ac-
cess routes and to determine the valve size. Peripheral vas-
cular access routes smaller than 6 mm diameter or
presenting severe annular calcifications were not consid-
ered good access sites for transfemoral TAVR, such as the
presence of abdominal aorta aneurysms and vessel tortuos-
ity. In these cases, TA was considered the best option. Pre-
dilation of small ilio-femoral arteries was never attempted.
The aortic valve annulus was assessed by injected aortic
CT-scan and trans-oesophageal echocardiography using the
diameter, the area and the perimeter for the stent-valve siz-
ing. Patients with chronic kidney failure underwent CT-
scan and coronary angiograms with low-dose of contrast.
Ta-Tavi
TA-TAVI were performed under general anaesthesia
through a left antero-lateral mini-thoracotomy at fifth
intercostal space. Intraoperative imaging included trans-
oesophageal echocardiography to confirm the valve size
and fluoroscopy. The apexes were prepared with con-
centric reinforced purse-string sutures and the devices
were the Sapien™ (2009–2010), the Sapien™ XT (2011–
2013) and the Sapien™ 3 (2014) valves (Edwards Life-
sciences, Irvine, CA). At the beginning of our series,
complication-free patients used to be transferred intu-
bated to the intensive care unit while, after getting more
experienced, patients were rapidly extubated in the cath-
lab and transferred to the intermediate care unit. As pre-
viously reported, echo-guided TA-TAVI were performed
without contrast injections [17].
Tf-Tavi
Patients with good vascular access underwent TF-TAVI
under general anaesthesia. According to our policy, the vas-
cular access was surgically performed with a 3 cm skin inci-
sion at the groin in order to puncture the femoral artery
under direct vision and prevent collateral damage. Cardiac
imaging was similar to TA-TAVI while the devices were the
Sapien™ valves, as mentioned above, but also the Medtronic
CoreValve™ (Medtronic inc, Minneapolis, MN). All
complication-free patients were extubated in the cath-lab
and transferred to the intermediate care unit.
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Statistical analysis
Statistical analysis was performed using R (version 3.2.2).
Continuous variables are summarized as mean ± Standard
Deviation and a t-test is used to compare the two
groups. Categorical variables are presented as numbers
and proportions (%) and a χ2 test or a Fisher exact test
is used to compare the two groups. Selected categorical
and continuous variables were analysed as risk-factors
for hospital mortality (death occurring within 30 days or
during the same hospitalization), disabling neurological
Fig. 1 Transapical and transfemoral TAVI distribution in our hospital during the study period
Table 1 Demographics, symptoms, risk factors
Overall
(N = 180)
TA-TAVI
(N = 90)
TF-TAVI
(N = 90)
p
Mean age (years) 82 ± 8.6 80 ± 8.5 83 ± 8.4 0.014
Men 82 (46%) 45 (50%) 37 (41%) 0.231a
COPD 38 (21%) 29 (32%) 9 (10%) <0.001a
Peripheral vascular disease 91 (51%) 71 (79%) 20 (22%) <0.001a
Previous vascular surgery 17 (9%) 13 (14%) 4 (4%) 0.039
Coronary disease 90 (50%) 54 (60%) 36 (40%) 0.007a
Previous coronary surgery 27 (15%) 19 (21%) 8 (9%) 0.022a
Previous cardiac surgery 40 (22%) 25 (28%) 15 (17%) 0.073a
Previous coronary angioplasty/stenting 28 (16%) 13 (14%) 15 (17%) 0.681a
Hypertension 117 (65%) 56 (62%) 61 (68%) 0.435a
Chronic renal failure 75 (42%) 38 (42%) 37 (41%) 0.880a
Dialysis 7 (4%) 4 (4%) 3 (3%) 1
Previous stroke 20 (11%) 11 (12%) 9 (10%) 0.635a
Diabetes (insulin) 30 (17%) 18 (20%) 12 (13%) 0.230a
Liver disease (CHILD score) 5 (3%) 3 (3%) 2 (2%) 1
pacemaker implantation 21 (12%) 9 (10%) 12 (13%) 0.486a
Chest radiotherapy 16 (9%) 7 (8%) 9 (10%) 0.600a
Preoperative critical state 15 (8%) 13 (14%) 2 (2%) 0.005
Porcelain aorta 12 (13%) 12 (13%) 0 (0%) 1
logistic Euro-SCORE (%) 31 ± 16 36 ± 15 25 ± 14 <0.001
Data presented as mean ± SD or N (%)
a Chi2 value, otherwise it’s a Fischer test or a T-Test value
COPD Chronic Obstructive Pulmonary Disease
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complications and major vascular complications, using
univariate logistic regression. A p-value below 0.05 was
considered statistically significant.
Results
Baseline clinical characteristics are described in Tables 1
and 2. Mean age was 80 ± 8.5 and 83 ± 8.4 years, in the
TA and TF-group, respectively (p = 0.014), while the sex
distribution was similar (50% male patients in the TA-
group and 41% in the TF-group, p = 0.231).
TA-group presented higher prevalence of comorbidi-
ties: more vascular disease (TA:79%, TF:22%, p < 0.001),
chronic pulmonary disease (TA:32%, TF:10%, p < 0.001),
higher prevalence of previously performed vascular
surgery (TA:14%, TF:4%, p = 0.039), higher coronary dis-
ease (TA:60%, TF:40%, p = 0.007), more previously per-
formed coronary surgery (TA:21%, TF:9%, p = 0.022)
and more previously performed cardiac surgery
(TA:28%, TF:17%, p = 0.073). Thirteen percent of pa-
tients in the TA-group had a porcelain aorta, versus
none in the TF-group. More patients with critical pre-
operative state were included in the TA-group (TA:14%,
TF:2%, p = 0.005) and the logistic Euro-SCORE was
higher in the TA-group (36 ± 15% for the TA-group
compared to 25 ± 4% for the TF-group; p < 0.001).
Successful implantation rate was 100% with longer
procedural time in the TF-group (TA:98 ± 33 min,
TF:127 ± 56 min, p < 0.001). Twelve patients had redo
Table 2 Preoperative imaging and valve hemodynamic
Overall
(N = 180)
TA-TAVI
(N = 90)
TF-TAVI (N = 90) p
Transaortic valve gradient (mmHg) 67 ± 26 62 ± 25 71 ± 28
Mean aortic valve area (cm2) 0.9 ± 3.4 1.2 ± 4.8 0.7 ± 0.2
Indexed aortic valve area (cm2/m2) 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1
Mean left ventricular ejection fraction (%) 54 ± 13 52 ± 12 56 ± 13
> 50% 101 (56%) 42 (47%) 59 (66%) 0.008*
30–50% 70 (39%) 42 (47%) 28 (32%)
< 30% 8 (4%) 6 (6%) 2 (2%)
Pulmonary hypertension 101 (56%) 48 (53%) 53 (59%) 0.453*
Mean aortic annulus diameter measured with CT-scan (mm) 23 ± 2.3 23 ± 2.5 24 ± 2.1
Mean aortic annulus diameter measured with TOE (mm) 23 ± 2.2 22 ± 2 22 ± 2.4
Mean distance: annulus-left coronary ostium (mm) 13 ± 2.9 12 ± 2 14 ± 3.2
Mean distance: annulus-right coronary ostium (mm) 134 ± 4 12 ± 3 15 ± 4.4
Data presented as mean ± SD or N (%). * Chi2 value
CT Computed Tomography, TOE Transoesophageal echocardiography
Table 3 Procedural data
Overall
(N = 180)
TA-TAVI (N = 90) TF-TAVI (N = 90) p
Sapien™ and Sapien XT™ 146 (81%) 86 (96%) 60 (67%)
Sapien 3™ 8 (4%) 4 (4%) 4 (4%)
CoreValve™ 26 (29%) NA 26 (29%)
Valve-in-valve in degenerated bioprosthesis 12 (7%) 7 (8%) 5 (6%) 0.550a
Bailout valve-in-valve for migration or malpositioning 7 (4%) 3 (3%) 4 (4%) 1
Mean valve size (mm) 25 ± 2.1 25 ± 1.9 25 ± 2.2
Valve size distribution
23 mm 75 (42%) 40 (44%) 35 (39%)
26 mm 77 (43%) 43 (48%) 44 (49%)
29 mm 14 (8%) 7 (8%) 7 (8%)
31 mm 4 (4%) 0 (0%) 4 (4%)
Procedural time (min) 113 ± 48 98 ± 33 127 ± 56 <0.001
Data presented as mean ± SD or N (%)
a Chi2 value, otherwise it’s a Fischer test or a T-Test value
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Table 4 Hospital outcome
Overall
(N = 180)
TA-TAVI
(N = 90)
TF-TAVI
(N = 90)
p
Hospital mortality 17 (9%) 8 (9%) 9 (10%) 0.799*
Cause of death
Respiratory failure 3 (2%) 3 (3%) 0 (0%)
Cardiac tamponade for annulus rupture 2 (1%) 0 (0%) 2 (2%)
Valve migration 1 (1%) 0 (0%) 1 (1%)
Myocardial infarction 1 (1%) 1 (1%) 0 (0%)
Heart failure 1 (1%) 0 (0%) 1 (1%)
Sudden death 1 (1%) 1 (1%) 0 (0%)
Cardiac arrest 2 (1%) 0 (0%) 2 (2%)
Life-threatening bleeding 1 (1%) 1 (1%) 0 (0%)
Multiple organ failure 1 (1%) 1 (1%) 0 (0%)
Disabling stroke 4 (2%) 1 (1%) 3 (3%)
Complications
Major vascular complications (including access related vascular complication, aortic
rupture and dissection, leg ischemia)
13 (7%) 3 (3%) 10 (11%) 0.081
Valve migration 3 (2%) 1 (1%) 2 (2%) 1
Major/life-threatening bleeding (including cardiac tamponade for aortic rupture or
ventricular tear)
7 (4%) 3 (3%) 4 (4%) 1
Disabling Stroke 5 (3%) 2 (2%) 3 (3%) 1
Coronary occlusion 1 (1%) 1 (1%) 0 (0%) 1
Bailout Sapien-in-Sapien for stent-valve migration or malpositioning 7 (4%) 3 (3%) 4 (4%) 1
Pneumonia 6 (3%) 5 (6%) 1 (1%) 0.211
Rethoracotomy for bleeding (TA)/pericardial drainage for tamponade (TF) 5 (3%) 3 (3%) 2 (2%) 1
Postoperative acute renal failure 4 (2%) 3 (3%) 1 (1%) 0.621
Dialysis 3 (2%) 3 (3%) 0 (0%) 0.246
New pacemaker for conduction abnormality 7 (4%) 2 (2%) 5 (6%) 0.444
Conversion to sternotomy 2 (1%) 2 (2%) 0 (0%) 0.497
Bailout cardiopulmonary bypass 4 (2%) 4 (4%) 0 (0%) 0.121
Early extubation 123 (68%) 40 (44%) 83 (92%) <0.001*
Intensive Care Unit stay (days) 1.4 ± 4.1
(median:0)
2.6 ± 5.5
(median:1)
0.2 ± 0.7
(median:0)
<0.001
Hospital stay (days) 11.7 ± 9.1
(median:9)
13.9 ± 9.5
(median:10)
9.4 ± 8.2
(median:8)
<0.001
Postoperative peak gradient (mmHg) 17.6 ± 9.5 16.7 ± 9.4 18.5 ± 9.5 0.219
Postoperative mean gradient (mmHg) 9.5 ± 5.3 9.2 ± 5.1 9.7 ± 5.5 0.563
Paravalvular leak: mild to severe 28 (16%) 5 (6%) 23 (26%) <0.001*
Trace of paravalvular leak 48 (27%) 15 (17%) 33 (37%)
Mild paravalvular leak 25 (14%) 5 (5%) 20 (22%)
Moderate paravalvular leak 2 (1%) 0 (0%) 2 (2%)
Severe paravalvular leak 1 (1%) 0 (0%) 1 (1%)
Data presented as mean ± SD or N (%)
*Chi2 value, otherwise it’s a Fischer test or a T-Test value
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valve-in-valve for degenerated aortic bioprosthesis, while
seven patients received two stent-valves because of a
stent-valve malpositioning or migration of the previously
implanted stent-valve.
Mean valve size and valve size distribution are listed in
Table 3.
With regards to hospital mortality and complication,
variables were analysed using VARC-2 definitions
(Table 4). Mortality for the two groups was similar
(TA:9%, TF:10%, p = 0.799) with a learning curve effect at
the beginning of our experience. Main cause of death in
TA-group was respiratory failure (3%), whereas in the TF-
group was disabling stroke (3%). Major vascular complica-
tions (including access-related vascular complication, aor-
tic dissection, acute leg ischemia and aortic rupture)
occurred more often in the TF-group (TA:3%, TF:11%,
p = 0.081) whereas major/life-threatening bleeding (in-
cluding cardiac tamponade) (TA:3%, TF:4%, p = 1), disab-
ling stroke (TA:2%, TF:3%, p = 1), and bailout valve-in-
valve for valve migration or malpositioning (TA:3%,
TF:4%, p = 1) were equally distributed (Fig. 2). Re-
thoracotomy for bleeding was performed in three TA and
a percutaneous pericardial drainage for tamponade was
urgently performed in two TF without further surgical ex-
ploration. Three patients in TA-group required dialysis.
As per the onset of new conduction abnormalities
leading to pacemaker implantation, five devices were im-
planted in the TF-group (2 in Sapien™ valves and 3 in
CoreValves™) and two in the TA-group (p = 0.444).
Echocardiographic controls showed similar peak
(TA:17 ± 9.4 mmHg, TF:18 ± 9.5, mmHg; p = 0.219) and
mean transvalvular gradients (TA:9.2 ± 5.1 mmHg,
TF:9.7 ± 5.5 mmHg; p = 0.563) in both groups. Mild to
severe paravalvular leaks were detected more in TF cases
(TA:5%, TF:25%, p < 0.001) (Table 4). Nevertheless,
moderate and severe paravalvular leaks were 0% in TA
and 3% in TF patients.
Selected variables were analysed as risk factors for hos-
pital mortality (Table 5), major vascular complications
(Table 6) and disabling neurological complications ac-
cording to the VARC-2 definitions (Table 7).
Concerning the hospital mortality, some variables were
statistically related to a higher risk of death: critical pre-
operative state (p = 0.026; OR, 4.25; 95% CI, 1.19–15.24),
major vascular complications (p = 0.001; OR, 8.07; 95% CI,
2.28–28.53), stent-valve migration (p = 0.014; OR, 21.6;
95% CI, 1.85–252), life-threatening bleeding (p = 0.001;
OR, 16.41; 95% CI, 3.31–81.29), disabling stroke (p = 0.003;
OR, 17.25; 95% CI, 2.66–112), renal failure (p = 0.022; OR,
10.73; 95% CI, 1.41–81.73), postoperative dialysis
(p = 0.014; OR, 21.6; 95% CI, 1.85–252) and need for emer-
gency cardiopulmonary bypass (p = 0.003; OR, 34.71; 95%
CI, 3.38–356) (Table 5). Early extubation (defined as extu-
bation within 4 h since the end of the index procedure) rep-
resents a protective factor against hospital mortality
(p = 0.001; OR, 0.16; 95% CI, 0.05–0.48).
About risk factors for major vascular complications,
use of emergency cardiopulmonary bypass was associ-
ated with higher rate of vascular injury (p = 0.010; OR,
15; 95% CI, 1.93–116) (Table 6). Concerning risk factors
for disabling stroke, postoperative acute renal failure and
dialysis were associated with poor neurological outcome
(p = 0.035; OR, 14.33; 95% CI, 1.21–169; and p = 0.020;
OR, 21.62; 95% CI, 1.61–290, respectively) (Table 7).
Discussion
Since the beginning of transcatheter aortic valve
therapies, the two main access routes are the
Fig. 2 Postoperative complications of TA and TF TAVI according to the VARC-2 definitions
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transfemoral and the transapical ones, allowing for
placement of balloon-expandable and self-expanding
valves of different size. However, the allocation to
one of these two access routes is still questionable
and based, at the time being, on the presence of a
severe vascular disease of the aorta or ilio-femoral
vessels, or on the possibility of performing the TF
case under sedation [18–22].
In our experience, patients allocated to the two groups
(all performed under general anaesthesia) showed differ-
ent comorbidity patterns: patients in the TA-group
presented higher prevalence of comorbidities, higher lo-
gistic Euro-SCORE and were more often in a preopera-
tive critical state. Thus, according to the fact that all
patients with severe vascular disease were automatically
included in the TA-group, we faced a TA population car-
rying a higher risk profile compared to the TF popula-
tion. However, the hospital mortality rate and
neurological outcome were similar.
Hospital mortality of our first TAVI series is in-line
with published preliminary results of TA vs TF showing
rates ranges between 5% and 15%, without statistical
Table 5 Univariate logistical regression analysis for hospital mortality (N:180)
Total n.0 n.1
163 17
Binary variables n.0 p.0 n.1 p.1 or or.sd or.ci95 p
Transfemoral procedure 81 49.7% 9 52.9% 1.14 1.67 0.42 3.10 0.799
Gender (M) 76 46.6% 6 35.3% 0.62 1.70 0.22 1.77 0.375
COPD 34 20.9% 4 23.5% 1.17 1.83 0.36 3.81 0.798
Vascular disease 81 49.7% 10 58.8% 1.45 1.68 0.52 3.98 0.476
Previous vascular surgery 16 9.8% 1 5.9% 0.57 2.90 0.07 4.62 0.602
Coronary disease 82 50.3% 8 47.1% 0.88 1.67 0.32 2.39 0.799
Previous CABG 25 15.3% 2 11.8% 0.74 2.19 0.16 3.42 0.696
Previous cardiac surgery 35 21.5% 5 29.4% 1.52 1.76 0.50 4.62 0.456
Previous STENT 23 14.1% 5 29.4% 2.54 1.78 0.82 7.87 0.107
Hypertension 108 66.3% 9 52.9% 0.57 1.67 0.21 1.57 0.278
Renal failure 66 40.5% 9 52.9% 1.65 1.67 0.61 4.51 0.326
Previous stroke 17 10.4% 3 17.6% 1.84 1.99 0.48 7.06 0.374
Diabetes 27 16.6% 3 17.6% 1.08 1.95 0.29 4.01 0.909
Pacemaker 19 11.7% 2 11.8% 1.01 2.21 0.21 4.77 0.989
Thorax radiotherapy 14 8.6% 2 11.8% 1.42 2.23 0.29 6.85 0.663
Critical state 11 6.7% 4 23.5% 4.25 1.92 1.19 15.24 0.026
Logistic EuroScore >20% 117 71.8% 12 70.6% 0.94 1.75 0.31 2.83 0.917
LVEF > 50% 91 55.8% 10 62.5% 1.32 1.72 0.46 3.80 0.608
Pulmonary hypertension 95 58.3% 6 35.3% 0.39 1.70 0.14 1.11 0.077
Valve-in-valve 11 6.7% 1 5.9% 0.86 2.94 0.10 7.13 0.892
Vascular complication 8 4.9% 5 29.4% 8.07 1.90 2.28 28.53 0.001
Valve migration 1 0.6% 2 11.8% 21.60 3.50 1.85 252 0.014
Life-threatening bleeding 3 1.8% 4 23.5% 16.41 2.26 3.31 81.29 0.001
Postoperative stroke 2 1.2% 3 17.6% 17.25 2.60 2.66 112 0.003
Pneumonia 4 2.5% 2 11.8% 5.30 2.48 0.90 31.37 0.066
Postoperative acute renal failure 2 1.2% 2 11.8% 10.73 2.82 1.41 81.73 0.022
Postoperative dialysis 1 0.6% 2 11.8% 21.60 3.50 1.85 252 0.014
New pacemaker 6 3.7% 1 5.9% 1.64 3.04 0.19 14.45 0.658
Cardiopulmonary bypass use 1 0.6% 3 17.6% 34.71 3.28 3.38 356 0.003
Early extubation (within 4 h) 118 72.4% 5 29.4% 0.16 1.75 0.05 0.48 0.001
Paravalvular leak (mild to severe) 25 15.4% 3 20.0% 1.37 1.98 0.36 5.21 0.644
OR odds ratio, OR.SD odds ratio standard deviation, OR.CI95 odds ratio 95% confidence interval, COPD chronic obstructive pulmonary disease, CABG coronary
artery bypass graft, LVEF left ventricular ejection fraction
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differences between the groups [18–22]. In a retrospect-
ive study, Van der Boon reported hospital mortality of
6.4% for TF and 15.7% for TA whereas in a prospective
study including thousand TAVI from Schymik and al.
the mortality was 6.5% for TF and 6.1% for TA [19, 21].
Murarka and al. also reported promising mortality rates
of 4.5% for TF and 5.3% for TA in a retrospective single-
centre experience [22]. However, none of these three
aforementioned studies was able to demonstrate a statis-
tically significant difference between the two popular
approaches.
In our report, neurological outcome showed similar
results for TA and TF (stroke = TA:2%, TF:3%, p = 1)
and we didn’t observe a significant difference. Our re-
sults are similar to published data. Schymik described
2.3% of stroke in the TF-group and 1.7% in the TA-
group with a non-significant p-value between the
groups. Other published series show similar conclusions
[18–22].
If we consider paravalvular leaks and access-related
vascular injuries, we identified a discrepancy in favour
for the TA approach. In particular, the mild to severe
paravalvular leak incidence (TA:6%, TF:26%, p < 0.001)
of our patients was similar to the one published in a
retrospective study from Greason and co-workers who
reported 12% of mild to severe paravalvular leak in TF
versus 8.4% in the TA group [18]. Nevertheless, the inci-
dence of moderate-severe PVL only is low in our groups
and almost similar between the two population. Murarka
and colleagues as well, have observed similar results
Table 6 Univariate logistical regression analysis for major vascular complications (N:180)
n.0 n.1
Total 167 13
Binary variables n.0 p.0 n.1 p.1 or or.sd or.ci95 p
Transfemoral procedure 80 47.9% 10 76.9% 3.62 1.97 0.96 13.64 0.057
Gender (M) 78 46.7% 4 30.8% 0.51 1.86 0.15 1.71 0.274
COPD 36 21.6% 2 15.4% 0.66 2.21 0.14 3.12 0.602
Vascular disease 84 50.3% 7 53.8% 1.15 1.78 0.37 3.58 0.806
Previous vascular surgery 15 9.0% 2 15.4% 1.84 2.26 0.37 9.10 0.453
Coronary disease 85 50.9% 5 38.5% 0.60 1.81 0.19 1.92 0.392
Previous CABG 26 15.6% 1 7.7% 0.45 2.89 0.06 3.62 0.455
Previous cardiac surgery 38 22.8% 2 15.4% 0.62 2.20 0.13 2.91 0.542
Hypertension 110 65.9% 7 53.8% 0.60 1.79 0.19 1.88 0.385
Renal failure 72 43.1% 3 23.1% 0.40 1.97 0.11 1.49 0.171
Diabetes 29 17.4% 1 7.7% 0.40 2.89 0.05 3.17 0.383
Pacemaker implantation 20 12.0% 1 7.7% 0.61 2.91 0.08 4.97 0.646
Thorax radiotherapy 14 8.4% 2 15.4% 1.99 2.27 0.40 9.87 0.401
Critical state 14 8.4% 1 7.7% 0.91 2.94 0.11 7.53 0.931
Logistic EuroSCORE >20% 121 72.5% 8 61.5% 0.61 1.81 0.19 1.96 0.404
LVEF > 50% 95 57.2% 6 46.2% 0.64 1.78 0.21 1.99 0.441
Pulmonary hypertension 96 57.5% 5 38.5% 0.46 1.81 0.15 1.47 0.192
Valve-in-valve 11 6.6% 1 7.7% 1.18 2.96 0.14 9.94 0.878
Hospital mortality 12 7.2% 5 38.5% 8.07 1.90 2.28 28.53 0.001
Disabling Stroke 4 2.4% 1 7.7% 3.40 3.18 0.35 32.82 0.291
Pericardial drainage/rethoracotomy for bleeding 4 2.4% 1 7.7% 3.40 3.18 0.35 32.82 0.291
Postoperative acute renal failure 3 1.8% 1 7.7% 4.56 3.30 0.44 47.19 0.204
Postoperative dialysis 2 1.2% 1 7.7% 6.87 3.53 0.58 81.36 0.126
Conversion to sternotomy 1 0.6% 1 7.7% 13.83 4.24 0.81 235 0.069
Cardiopulmonary bypass use 2 1.2% 2 15.4% 15.00 2.85 1.93 116 0.010
Early extubation (within 4 h) 117 70.1% 6 46.2% 0.37 1.79 0.12 1.14 0.084
Paravalvular leak (mild to severe) 26 15.8% 2 16.7% 1.07 2.23 0.22 5.16 0.934
OR odds ratio, OR.SD odds ratio standard deviation, OR.CI95 odds ratio 95% confidence interval, COPD chronic obstructive pulmonary disease, CABG coronary
artery bypass graft, LVEF left ventricular ejection fraction
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between TA and TF with 7.6% of moderate-severe para-
valvular leaks in TF-group and 7% in TA-group
(p = 0.999) [22]. The reason for some discrepancies in
paravalvular leak rate in the 2 techniques can be due to
the more direct and more precise valve positioning dur-
ing TA cases but this is not proved yet. Moreover, as far
as paravalvular leaks are concerned, we have to admit
that, in our experience, we have seen a great improve-
ment after the launch of last-generation Sapien™ 3 valve
featuring an innovative outer skirt preventing leaks.
Therefore, we can speculate that, in the future, the use
of this valve (or other stent-valves addressing the issue
of paravalvular leaks with improved technologies) will
reduce the incidence of clinically-relevant leaks.
Regarding the major access-related vascular compli-
cation rate in our group, this was higher in TF pa-
tients but the result is not statistically significant
(TA:3%, TF:11%, p = 0.081). In comparison, if we look
at recent publications we can see that the incidence
of this complication is more prevalent in TF as well:
Schymik reported 17.5% of major vascular complica-
tions in TF versus 2.5% in TA (p = <0.0001) [19].
Murarka and colleagues observed similar trend, with
12.1% of major vascular complications in the TF-
group versus 0% in the TA-group [22]. New gener-
ation devices with low-profile introducer sheaths and
small delivery systems will help decreasing the inci-
dence of access site vascular complications in future
reports.
As long as the intensive care unit length of stay and
extubation time are concerned, in our study these num-
bers were slightly longer for TA-TAVI patients and this
finding is justified by the fact that at the beginning TA pa-
tients were all transferred, intubated, to the intensive care
unit and then transferred to the intermediate care unit on
postoperative day one. On the other hand, since the begin-
ning, complication-free transfemoral TAVI cases were
rapidly extubated in the cath-lab and transferred to the
intermediate care unit. However, these results are not
comparable with other centres as local hospital policies
and daily practice can be very different and, sometimes,
they can change with acquired experience.
An important point of discussion is the development
of new TAVI devices: new generations of stent-valve
equipment have more performant designs and low-
profile delivery systems assuring lower incidence of para-
valvular leak and vascular injury. This development can
have a great impact in future reports on TAVI mortality
and morbidity allowing for the use of these new devices
in mid-risk and younger patients.
Our study presents some limitations. It is a retrospect-
ive study describing the hospital outcome of first cases
Table 7 Univariate logistical regression analysis for neurological complications (N:180)
n.0 n.1
Total 175 5
Binary variables n.0 p.0 n.1 p.1 or or.sd or.ci95 p
Transfemoral procedure 87 49.7% 3 60.0% 1.52 2.52 0.25 9.30 0.652
Gender (M) 81 46.3% 1 20.0% 0.29 3.09 0.03 2.65 0.273
COPD 37 21.1% 1 20.0% 0.93 3.11 0.10 8.59 0.951
Vascular disease 88 50.3% 3 60.0% 1.48 2.52 0.24 9.09 0.670
Coronary disease 88 50.3% 2 40.0% 0.66 2.52 0.11 4.04 0.652
Previous CABG 26 14.9% 1 20.0% 1.43 3.12 0.15 13.33 0.752
Previous cardiac surgery 38 21.7% 2 40.0% 2.40 2.54 0.39 14.91 0.346
Previous coronary stenting 27 15.4% 1 20.0% 1.37 3.12 0.15 12.74 0.782
Hypertension 114 65.1% 3 60.0% 0.80 2.53 0.13 4.93 0.812
Previous stroke 19 10.9% 1 20.0% 2.05 3.14 0.22 19.33 0.530
Diabetes 29 16.6% 1 20.0% 1.26 3.12 0.14 11.67 0.840
LVEF > 50% 97 55.7% 4 80.0% 3.18 3.09 0.35 28.99 0.306
Pulmonary hypertension 98 56.0% 3 60.0% 1.18 2.52 0.19 7.23 0.859
Hospital mortality 14 8.0% 3 60.0% 17.25 2.60 2.66 112 0.003
Vascular complication 12 6.9% 1 20.0% 3.40 3.18 0.35 32.82 0.291
Postoperative acute renal failure 3 1.7% 1 20.0% 14.33 3.53 1.21 169 0.035
Postoperative dialysis 2 1.1% 1 20.0% 21.62 3.76 1.61 290 0.020
Early extubation (within 4 h) 121 69.1% 2 40.0% 0.30 2.53 0.05 1.83 0.191
OR odds ratio, OR.SD odds ratio standard deviation, OR.CI95 odds ratio 95% confidence interval, COPD chronic obstructive pulmonary disease, CABG coronary
artery bypass grafting, LVEF left ventricular ejection fraction
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of TA and TF TAVI performed at our Institution with a
relatively small number of patients. The population in-
cluded the preliminary TAVI experience of our hospital
and, therefore, a physiologic learning curve can have
negatively affected the first-period clinical outcome. The
patient-selection process has also changed during the
study period as well as the use of new-generation
devices.
Conclusion
In conclusion, this study shows our first TAVI experi-
ence and results are similar to published data. Based on
our findings, we can confirm that transcatheter tech-
niques are promising and provide good hospital out-
comes. Improved surgeons’ and cardiologists’ skills and
the advent of last-generation devices will facilitate the
stent-valve delivery and will help improving the risk of
vascular complication, neurological complication and
paravalvular leak, also for use in intermediate-risk
patients.
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